From our laboratories in Geneva, Switzerland, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their programs, helping them reach patients with new treatments faster.
Selexis partners' clinical and commercial pipelines using SUREtechnology™
Unleashing the power of novel protein therapeutics to transform the care of and prospects for millions of patients who suffer from life-threatening diseases depends heavily on continued advances in technologies and methods for protein expression. This is particularly critical for medicines that are based on recombinant proteins, such as monoclonal antibodies and difficult-to-express proteins, including Fc-fusion proteins, bi-specific monoclonal antibodies, and novel scaffolds. Selexis is a scientific pioneer and global leader in mammalian (suspension-adapted CHO-K1) cell line generation that has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for more than a decade. Selexis’s proprietary SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.